Fig. 4 in Dammarane-type saponins with proprotein convertase subtilisin/kexin type 9 inhibitory activity from Gynostemma pentaphyllum

Fig. 4. Effects of compounds 1–11 on cell viabilities and PCSK9 inhibitory activities in HepG2 cells. (A–B) The cell viability assay of compounds 1–11 with different concentrations (5, 10, 20, 40, and 80 μM) in HepG2 cells. (C) Effect of compounds 1–11 (20 μM) and BBR (berberine, 10 μM) on the expression of PCSK9 in HepG2 cells. (D) Effect of compounds 1–11 (10 μM) and BBR (berberine, 10 μM) on the expression of PCSK9 in HepG2 cells. (E) Effect of compounds 2, 5 (5 μM) and BBR (berberine, 10 μM) on the expression of PCSK9 in HepG2 cells. The expression of PCSK9 was assayed by ELISA in HepG2 cells treated with compounds 1–11 and BBR (berberine) for 24 h. The results were calculated as the means ± SD of three independent experiments. ###p <0.001 vs control group; *p <0.05, **p <0.01, ***p <0.001 vs model group.